Anti-ribosomal P antibodies in systemic lupus erythematosus: a case-control study correlating hepatic and renal disease.
We report a case-control study of the occurrence of liver and kidney disease in 20 systemic lupus erythematosus (SLE) patients with anti-ribosomal P antibodies and 20 age-, sex-, and race-matched (control group) SLE patients without anti-P antibodies. In the group with anti-P antibodies, 7 patients were found to have had liver disease, compared with only 1 in the control group (P = 0.03), and 14 anti-P (+) patients have had kidney disease, compared with 4 in the control group (P = 0.01). A major serological difference between the groups was an increased prevalence of anti-dsDNA in the anti-P positive group (12/20) vs the control group (4/20), P = 0.02. These statistically significant differences suggest that antibodies to ribosomal P identify a subset of SLE patients at higher risk for liver and kidney involvement, in addition to the previously recognized risk for neuropsychiatric disease.
Rheumatology Section, University of Oklahoma Medical Center, Oklahoma Medical Research Foundation, Oklahoma City 73104.
M
M
Hulsey
R
R
Goldstein
L
L
Scully
W
W
Surbeck
M
M
Reichlin
D000293:Adolescent; D000328:Adult; D000906:Antibodies / Q000097:blood*; D016022:Case-Control Studies; D005260:Female; D006801:Humans; D007674:Kidney Diseases / Q000453:epidemiology* / Q000276:immunology*; D008107:Liver Diseases / Q000453:epidemiology* / Q000276:immunology*; D008180:Lupus Erythematosus, Systemic / Q000453:epidemiology* / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D015800:Protozoan Proteins; D012269:Ribosomal Proteins / Q000276:immunology*
D000906:Antibodies; C064601:L12E protein, Trypanosoma cruzi; D015800:Protozoan Proteins; D012269:Ribosomal Proteins